Skip to main content
Log in

Initial Clinical Experience with Clinafloxacin in the Treatment of Serious Infections

  • Miscellaneous Clinical Studies
  • Published:
Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Fuchs PC, Barry AL, Pfaller MA, et al. Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates. Antimicrob Agents Chemother 1991; 35 (4): 764–6

    Article  PubMed  CAS  Google Scholar 

  2. Jones RN, Johnson DM. Modification for disk diffusion susceptibility testing criteria of CLF (CI-960, AM-1091, CP127371) and fleroxacin (RO 23-6240, AM-833) following studies with a challenge-panel of ciprofloxacin-resistant clinical isolates. Diagn Microbiol Infect Dis. In press

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tack, K.J., McGuire, N.M. & Eiseman, I.A. Initial Clinical Experience with Clinafloxacin in the Treatment of Serious Infections. Drugs 49 (Suppl 2), 488–491 (1995). https://doi.org/10.2165/00003495-199500492-00145

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199500492-00145

Keywords

Navigation